Magro G, Molinelli S, Mairani A, Mirandola A, Panizza D, Russo S, Ferrari A, Valvo F, Fossati P, Ciocca M
Department of Physics-University of Pavia, I-27100 Pavia, Italy. Istituto Nazionale di Fisica Nucleare (INFN)-I-27100 Pavia, Italy. Centro Nazionale di Adroterapia Oncologica (CNAO Foundation)-I-27100 Pavia, Italy.
Phys Med Biol. 2015 Sep 7;60(17):6865-80. doi: 10.1088/0031-9155/60/17/6865. Epub 2015 Aug 24.
This study was performed to evaluate the accuracy of a commercial treatment planning system (TPS), in optimising proton pencil beam dose distributions for small targets of different sizes (5-30 mm side) located at increasing depths in water. The TPS analytical algorithm was benchmarked against experimental data and the FLUKA Monte Carlo (MC) code, previously validated for the selected beam-line. We tested the Siemens syngo(®) TPS plan optimisation module for water cubes fixing the configurable parameters at clinical standards, with homogeneous target coverage to a 2 Gy (RBE) dose prescription as unique goal. Plans were delivered and the dose at each volume centre was measured in water with a calibrated PTW Advanced Markus(®) chamber. An EBT3(®) film was also positioned at the phantom entrance window for the acquisition of 2D dose maps. Discrepancies between TPS calculated and MC simulated values were mainly due to the different lateral spread modeling and resulted in being related to the field-to-spot size ratio. The accuracy of the TPS was proved to be clinically acceptable in all cases but very small and shallow volumes. In this contest, the use of MC to validate TPS results proved to be a reliable procedure for pre-treatment plan verification.
本研究旨在评估一种商业治疗计划系统(TPS)在优化质子笔形束剂量分布方面的准确性,该剂量分布针对位于水中不同深度的不同尺寸(边长5 - 30毫米)的小靶区。TPS分析算法以实验数据和之前针对所选束流线验证过的FLUKA蒙特卡罗(MC)代码为基准进行测试。我们测试了西门子syngo(®) TPS计划优化模块,针对水模体立方体,将可配置参数设定为临床标准,以均匀覆盖靶区至2 Gy(RBE)剂量处方作为唯一目标。实施计划,并使用校准后的PTW Advanced Markus(®)电离室在水中测量每个体积中心的剂量。还在模体入口窗口放置了一张EBT3(®)胶片,用于获取二维剂量图。TPS计算值与MC模拟值之间的差异主要归因于不同的横向扩展建模,并且与野到光斑尺寸比有关。在所有情况下,除了非常小且浅的体积外,TPS的准确性在临床上被证明是可接受的。在这种情况下,使用MC来验证TPS结果被证明是一种用于治疗前计划验证的可靠程序。